BR112022021445A2 - Métodos e composições para tratar condições inflamatórias associadas com doença infecciosa - Google Patents

Métodos e composições para tratar condições inflamatórias associadas com doença infecciosa

Info

Publication number
BR112022021445A2
BR112022021445A2 BR112022021445A BR112022021445A BR112022021445A2 BR 112022021445 A2 BR112022021445 A2 BR 112022021445A2 BR 112022021445 A BR112022021445 A BR 112022021445A BR 112022021445 A BR112022021445 A BR 112022021445A BR 112022021445 A2 BR112022021445 A2 BR 112022021445A2
Authority
BR
Brazil
Prior art keywords
compositions
conditions associated
methods
infectious disease
inflammatory conditions
Prior art date
Application number
BR112022021445A
Other languages
English (en)
Inventor
Allen PETTINE Kenneth
Hicok Kevin
Alexander MOSELEY Timothy
Original Assignee
Direct Biologics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Direct Biologics Llc filed Critical Direct Biologics Llc
Publication of BR112022021445A2 publication Critical patent/BR112022021445A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/366—Thrombomodulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Endocrinology (AREA)

Abstract

MÉTODOS E COMPOSIÇÕES PARA TRATAR CONDIÇÕES INFLAMATÓRIAS ASSOCIADAS COM DOENÇA INFECCIOSA. São divulgadas neste documento composições compreendendo uma preparação de células-tronco mesenquimais (MSC) e uma ou mais biomoléculas e o uso das referidas composições para o tratamento ou uma infecção microbiana ou os sintomas ou condições patológicas secundárias associadas à referida infecção.112022021445-6
BR112022021445A 2020-04-22 2021-04-22 Métodos e composições para tratar condições inflamatórias associadas com doença infecciosa BR112022021445A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063013865P 2020-04-22 2020-04-22
US202063198706P 2020-11-06 2020-11-06
PCT/US2021/028686 WO2021216903A1 (en) 2020-04-22 2021-04-22 Methods and compositions for treating inflammatory conditions associated with infectious disease

Publications (1)

Publication Number Publication Date
BR112022021445A2 true BR112022021445A2 (pt) 2023-01-10

Family

ID=78270105

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022021445A BR112022021445A2 (pt) 2020-04-22 2021-04-22 Métodos e composições para tratar condições inflamatórias associadas com doença infecciosa

Country Status (11)

Country Link
US (1) US20230159932A1 (pt)
EP (1) EP4138867A4 (pt)
JP (1) JP2023523588A (pt)
KR (1) KR20230004709A (pt)
CN (1) CN115843253A (pt)
AU (1) AU2021261384A1 (pt)
BR (1) BR112022021445A2 (pt)
CA (1) CA3180973A1 (pt)
IL (1) IL297563A (pt)
MX (1) MX2022013301A (pt)
WO (1) WO2021216903A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102317052B1 (ko) * 2020-05-04 2021-10-25 주식회사 티에스셀바이오 태반 유래의 세포외 소포의 항염증 항바이러스 효과 조성물
CN113789333B (zh) * 2021-09-07 2023-07-14 中国人民解放军军事科学院军事医学研究院 Chi3l1在调控hUC-MSCs抑制Th17分化介导的免疫调节作用上的应用
CN114469996B (zh) * 2021-12-23 2023-10-20 中国医学科学院医学生物学研究所 一种包含miR-135b-5p的外泌体及在抗轮状病毒感染中的应用
US20230313191A1 (en) * 2022-03-29 2023-10-05 Direct Biologics Llc Rna comprising secretomes and methods of their use
CN115478117A (zh) * 2022-05-11 2022-12-16 江苏命码生物科技有限公司 一种用于早期预警新型冠状病毒中重型、危重型病例的试剂盒
US11878036B2 (en) 2022-05-25 2024-01-23 Neuvian LLC Vaginal care compositions and methods of improving vaginal health
JP7406059B1 (ja) 2022-10-20 2023-12-27 防衛装備庁長官 急性ストレス評価用データの生成方法
CN116656699B (zh) * 2023-05-16 2024-05-31 南京农业大学 SESN2和chi-miR-130b-3p在调节由玉米赤霉烯酮诱导的颗粒细胞凋亡中的应用
CN116515995B (zh) * 2023-06-29 2023-09-19 迈杰转化医学研究(苏州)有限公司 一种检测噬血细胞性淋巴组织细胞增生症的血清microRNA标志物及其应用
CN116875550B (zh) * 2023-09-08 2023-12-26 天津市肿瘤医院（天津医科大学肿瘤医院） 一种FABP4+C1q+巨噬细胞及其制备方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190000886A1 (en) * 2016-03-16 2019-01-03 Duncan ROSS Method of treatment of osteochondral defects
EA202091219A1 (ru) * 2017-11-16 2020-08-18 Селулэрити, Инк. Культивирование плаценты с целью выделения экзосом
CN112334190B (zh) * 2018-04-30 2024-09-20 儿童医学中心公司 间充质基质细胞外排体及其用途
IT201900003639A1 (it) * 2019-03-13 2020-09-13 Evobiotech S R L Composizioni di vescicole extracellulari (EV) derivate da piante e loro usi

Also Published As

Publication number Publication date
KR20230004709A (ko) 2023-01-06
AU2021261384A1 (en) 2022-12-22
JP2023523588A (ja) 2023-06-06
CA3180973A1 (en) 2021-10-28
EP4138867A4 (en) 2024-05-01
WO2021216903A1 (en) 2021-10-28
CN115843253A (zh) 2023-03-24
EP4138867A1 (en) 2023-03-01
MX2022013301A (es) 2023-02-14
IL297563A (en) 2022-12-01
US20230159932A1 (en) 2023-05-25

Similar Documents

Publication Publication Date Title
BR112022021445A2 (pt) Métodos e composições para tratar condições inflamatórias associadas com doença infecciosa
BR112021023814A2 (pt) Inibidores de proteases de cisteína e métodos de uso das mesmas
BR112022010349A2 (pt) Compostos bifuncionais para degradar btk por meio de via da ubiquitina-proteossoma
BR112021022666A2 (pt) Frações de separação e seus métodos e uso
BR112022016382A2 (pt) Triptaminas específicas para o uso no tratamento de doenças do humor
BR112018075288A2 (pt) métodos para diagnóstico de infecções bacterianas e virais
BR112022003335A2 (pt) Conjugados de il-2 e métodos de uso para tratar doenças autoimunes
BR112015019066A2 (pt) Anticorpos humanos para proteína f do vírus respiratório sincicial e métodos de uso dos mesmos
BR112019009106A2 (pt) método para aumentar os níveis de secreção sem afetar as funções biológicas de il-2 de humano recombinante e suas proteínas mutantes derivadas, proteínas obtidas, e, usos do método e das proteínas obtidas
BR112022002837A2 (pt) Anticorpo anti-vd1 ou fragmento do mesmo, anticorpo multiespecífico isolado ou fragmento do mesmo, anticorpo humano e anticorpo multiespecífico isolado humano ou fragmento do mesmo
BR112021017738A8 (pt) Células-tronco mesenquimais imunomoduladoras
BR112017024891A2 (pt) conjunto de anel de turbina
AR092188A1 (es) ANTICUERPOS HUMANOS PARA GFRa3 Y METODOS PARA SU USO
BR112012019881A2 (pt) proteínas de domínio estrutural baseadas na fibronectina que ligam-se à il-23
BR112015017307A2 (pt) composições de espécies com baixa acidez e métodos para produção e uso das mesmas
BR112017011067A2 (pt) cepas e métodos para a partição de energia em ruminantes
BR112022015969A2 (pt) Composições e métodos para enxerto de células editadas de base
BR112021023048A2 (pt) Moléculas de ligação a cd19 e usos das mesmas
BR112022001359A2 (pt) Método e composição para anticorpos anti-cd73 e variantes
BR112022016456A2 (pt) Formulações de anticorpos anti-tslp humanos e métodos de uso dos mesmos
BR112023009172A2 (pt) Métodos, sistemas e kits para tratamento de doenças inflamatórias direcionados à tl1a
BR112021025116A2 (pt) Células linfocíticas ativadas e métodos de uso das mesmas para tratar câncer e condições infecciosas
BR112021019120A2 (pt) Células t específicas para antígenos de múltiplos vírus respiratórios e métodos de produção e uso das mesmas terapeuticamente
UY31325A1 (es) Composiciones y métodos para tratar enfermedades y trastornos inmunologicos e inflamatorios
CL2021002837A1 (es) Formas sólidas de un inhibidor de glyt1